Drug Delivery Devices and Propellants
Topical delivery of medications to the airway as medical aerosols is the first line treatment of asthma. Medical aerosols are produced by a range of devices and each device has its own characteristics, method of operation, and target patient population. Aerosol delivery can be a challenge as the structure of the airways is designed to minimize lung penetration of many aerosols found in the air around us; from dust and pollen to airborne pathogens. The smaller the airway, the greater the flow turbulence and therefore, the greater the volume of particles filtered. Thus, delivery of medical aerosols to children is often an order of magnitude less than adults . This challenge is greater in asthma when there is airflow limitation, inflammation, excess mucus secretion, and airway remodeling . Patient education for proper device use is as critical as proper device selection for effective therapy [3, 4]. In this chapter, we discuss the characteristics of aerosol devices and the best techniques for aerosol delivery in patients with asthma.
KeywordsAcute Asthma Inspiratory Flow Beclomethasone Dipropionate Geometric Standard Deviation Dose Inhaler
Unable to display preview. Download preview PDF.
- 3.Fink JB, Rubin BK. Problems with inhaler use: A call for improved clinician and patient education. Resp Care 2005;50:1360–75.Google Scholar
- 12.Bisgaard H et al. Inspiratory flow rate through the Diskus/Accuhaler inhaler and Turbuhaler inhaler in children with asthma. J Aerosol Med 1995;8:100.Google Scholar
- 14.Thiel CG. From Susie's question to CFC free: an inventor's perspective on forty years of MDI development and regulation. In: Dalby RN, Byron P, Farr SY, editors. Respiratory drug delivery V. Buffalo Grove: Interpharm Press; 1996:115–123.Google Scholar
- 15.Montreal Protocol, September 16, 1987, S. Treaty Doc. No. 10, 100th Cong., 1st sess., 26 I. L. M. 1541 (1987) found at http://www.unep.org/ozone/Montreal-Protocol/Montreal-Protocol2000.shtmlGoogle Scholar
- 17.Lasserson TJ, Cates CK, Jones AB, Steele EH, White J. Fluticasone versus HFA-beclomethasone dipropionate for chronic asthma in adults and children. Cochrane Database Syst Rev 2006;19(2):CD005309.Google Scholar
- 19.Anhoj J, Thorsson L, Bisgaard H. Lung deposition of inhaled drugs increases with age. Am J Resp Crit Care Med 2000;162:1819–22.Google Scholar
- 36.Rubin BK, Fink JB. Optimizing aerosol delivery by pressurized metered dose inhalers. Resp Care 2005;50:1191–97.Google Scholar
- 41.Rubin BK. Bye-bye, blow-by. Resp Care 2007 August (in press).Google Scholar
- 42.GINA Global Strategy for Asthma Management and Prevention. Updated 2003. NIH Publication NO 02-3659.Google Scholar
- 44.Cates CJ, Rowe BH. Holding chambers versus nebulisers for beta-agonist treatment of acute asthma (Cochrane Review). In: The Cochrane Library, 2000; Issue 2 (CD000052). Oxford: Update Software).Google Scholar